Indivior (LON:INDV – Get Free Report) had its price objective upped by investment analysts at Morgan Stanley from GBX 2,500 ($32.10) to GBX 2,700 ($34.66) in a research note issued to investors on Thursday, FlyOnTheWall reports. Morgan Stanley’s target price indicates a potential upside of 46.34% from the company’s previous close.
Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,330 ($29.91) target price on shares of Indivior in a research note on Monday, June 5th.
Indivior Stock Performance
Shares of INDV opened at GBX 1,845 ($23.69) on Thursday. The company has a debt-to-equity ratio of 387.50, a current ratio of 1.08 and a quick ratio of 1.52. The stock has a 50-day moving average of GBX 1,742.15 and a 200-day moving average of GBX 1,644.67. The company has a market cap of £2.54 billion, a PE ratio of -6,362.07, a P/E/G ratio of -5.57 and a beta of 0.04. Indivior has a one year low of GBX 1,330 ($17.08) and a one year high of GBX 2,020 ($25.93).
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia.
Featured Stories
- Five stocks we like better than Indivior
- Consumer Staples Stocks, Explained
- 3 Best Meme ETFs to Buy Now
- Earnings Per Share Calculator: How to Calculate EPS
- XPO Keeps Reaching New Highs: Markets Love the Stock
- How to Read Stock Charts for Beginners
- Starbucks Market at a Turning Point: Is a Breakout Imminent?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
